Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Development of rotational intraperitoneal pressurized aerosol chemotherapy to enhance drug delivery into the peritoneum.

Tytuł:
Development of rotational intraperitoneal pressurized aerosol chemotherapy to enhance drug delivery into the peritoneum.
Autorzy:
Park SJ; Department of Obstetrics and Gynecology, Seoul National University Hospital, Seoul, Republic of Korea.
Lee EJ; Department of Obstetrics and Gynecology, Seoul National University Hospital, Seoul, Republic of Korea.
Lee HS; Interdisciplinary Program in Bioengineering, Seoul National University Graduate School, Seoul, Republic of Korea.
Kim J; Interdisciplinary Program in Bioengineering, Seoul National University Graduate School, Seoul, Republic of Korea.
Park S; Institute of Animal Molecular Biotechnology and Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul, Republic of Korea.
Ham J; Institute of Animal Molecular Biotechnology and Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul, Republic of Korea.
Mun J; Department of Obstetrics and Gynecology, Seoul National University Hospital, Seoul, Republic of Korea.
Paik H; Department of Obstetrics and Gynecology, Seoul National University Hospital, Seoul, Republic of Korea.
Lim H; Department of Obstetrics and Gynecology, Seoul National University Hospital, Seoul, Republic of Korea.
Seol A; Department of Obstetrics and Gynecology, Seoul National University Hospital, Seoul, Republic of Korea.
Yim GW; Department of Obstetrics and Gynecology, Dongguk University Ilsan Hospital, Goyang, Korea.
Shim SH; Department of Obstetrics and Gynecology, Research Institute of Medical Science, Konkuk University School of Medicine, Seoul, Republic of Korea.
Kang BC; Department of Experimental Animal Research, Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea.
Chang SJ; Department of Obstetrics and Gynecology, Ajou University School of Medicine, Suwon, Republic of Korea.
Lim W; Department of Food and Nutrition, Kookmin University, Seoul, Republic of Korea.
Song G; Institute of Animal Molecular Biotechnology and Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul, Republic of Korea.
Kim JW; Department of Obstetrics and Gynecology, Seoul National University Hospital, Seoul, Republic of Korea.
Lee N; Department of Obstetrics & Gynecology, CHA Gangnam Medical Center, CHA University, Seoul, Republic of Korea.
Park JW; Department of Surgery, Seoul National University College of Medicine, Seoul, Republic of Korea.
Lee JC; Department of Biomedical Engineering, Seoul National University College of Medicine, Seoul, Republic of Korea.; Institute of Medical and Biological Engineering, Medical Research Center, Seoul National University, Seoul, South Korea.
Kim HS; Department of Obstetrics and Gynecology, Seoul National University Hospital, Seoul, Republic of Korea.
Corporate Authors:
KoRIA* trial group
Źródło:
Drug delivery [Drug Deliv] 2021 Dec; Vol. 28 (1), pp. 1179-1187.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Publication: 2015->: Abingdon, Oxford : Taylor & Francis
Original Publication: Orlando, FL : Academic Press, c1993-
MeSH Terms:
Antibiotics, Antineoplastic/*administration & dosage
Antibiotics, Antineoplastic/*pharmacokinetics
Doxorubicin/*administration & dosage
Doxorubicin/*pharmacokinetics
Drug Delivery Systems/*methods
Peritoneum/*drug effects
Aerosols ; Animals ; Antibiotics, Antineoplastic/adverse effects ; Doxorubicin/adverse effects ; Swine
References:
Cancer Treat Rev. 2001 Dec;27(6):365-74. (PMID: 11908929)
Br J Surg. 2017 May;104(6):669-678. (PMID: 28407227)
Anaesth Intensive Care. 1993 Apr;21(2):163-71. (PMID: 8517506)
Eur J Surg Oncol. 2018 Nov;44(11):1793-1799. (PMID: 29871821)
Surg Endosc. 2017 Apr;31(4):1778-1784. (PMID: 27631320)
Front Physiol. 2018 Jun 15;9:738. (PMID: 29962968)
J Am Coll Cardiol. 1998 Nov;32(5):1389-96. (PMID: 9809953)
Gynecol Oncol. 2015 May;137(2):223-8. (PMID: 25701703)
World J Gastrointest Oncol. 2010 Feb 15;2(2):109-16. (PMID: 21160929)
Anticancer Res. 2016 Sep;36(9):4595-600. (PMID: 27630300)
Gland Surg. 2021 Mar;10(3):1271-1275. (PMID: 33842275)
J Cancer Res Clin Oncol. 2016 Nov;142(11):2275-80. (PMID: 27590613)
World J Gastrointest Oncol. 2020 May 15;12(5):569-581. (PMID: 32461788)
Anticancer Res. 2021 Nov;41(11):5489-5498. (PMID: 34732419)
Perit Dial Int. 2019 Sep-Oct;39(5):455-464. (PMID: 31337699)
Ann Surg Oncol. 2013 Oct;20(11):3504-11. (PMID: 23765417)
J Clin Oncol. 2018 Jul 1;36(19):1922-1929. (PMID: 29746229)
Cancers (Basel). 2020 Mar 09;12(3):. (PMID: 32182896)
Eur J Surg Oncol. 2021 Jan;47(1):123-127. (PMID: 32561204)
Tissue Cell. 2017 Feb;49(1):95-105. (PMID: 27890350)
Eur J Cancer. 1998 Jan;34(1):148-54. (PMID: 9624250)
Ann Surg Oncol. 2016 Apr;23(4):1220-4. (PMID: 26553440)
Ann Surg Oncol. 2014 Feb;21(2):553-9. (PMID: 24006094)
Lancet Oncol. 2019 Jul;20(7):e368-e377. (PMID: 31267971)
Cancer Res. 1980 Feb;40(2):256-60. (PMID: 6766084)
Dis Colon Rectum. 2015 Aug;58(8):743-52. (PMID: 26163953)
Surg Endosc. 2012 Jul;26(7):1849-55. (PMID: 22580869)
Medicine (Baltimore). 2019 Dec;98(50):e18355. (PMID: 31852138)
Pleura Peritoneum. 2020 May 15;5(2):20200109. (PMID: 32566727)
Lancet Gastroenterol Hepatol. 2019 Oct;4(10):761-770. (PMID: 31371228)
Cancer Treat Res. 1996;82:359-74. (PMID: 8849962)
J Surg Oncol. 2019 Apr;119(5):653-659. (PMID: 30811033)
Clin Exp Metastasis. 2018 Oct;35(7):635-640. (PMID: 30062506)
Ann Surg Oncol. 2013 Jul;20(7):2311-6. (PMID: 23377563)
World J Surg Oncol. 2016 Apr 29;14:128. (PMID: 27125996)
Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S161-92. (PMID: 17161157)
Vaccines (Basel). 2018 Aug 10;6(3):. (PMID: 30103457)
Contributed Indexing:
Keywords: Intraperitoneal chemotherapy; doxorubicin; drug delivery; peritoneal metastasis; pharmacokinetics
Substance Nomenclature:
0 (Aerosols)
0 (Antibiotics, Antineoplastic)
80168379AG (Doxorubicin)
Entry Date(s):
Date Created: 20210614 Date Completed: 20211117 Latest Revision: 20220716
Update Code:
20240105
PubMed Central ID:
PMC8204987
DOI:
10.1080/10717544.2021.1937382
PMID:
34121568
Czasopismo naukowe
This study aims to evaluate the drug distribution, tissue concentrations, penetration depth, pharmacokinetic properties, and toxicities after rotational intraperitoneal pressurized aerosol chemotherapy (RIPAC) in pigs. Because relevant medical devices have not been introduced, we developed our prototype of pressurized intraperitoneal aerosol chemotherapy (PIPAC) and RIPAC by adding a conical pendulum motion device for rotating the nozzle. RIPAC and PIPAC were conducted using 150 ml of 1% methylene blue to evaluate the drug distribution and 3.5 mg of doxorubicin in 50 ml of 0.9% NaCl to evaluate the tissue concentrations and penetration depth, pharmacokinetic properties, and toxicities. All agents were sprayed as aerosols via the nozzle, DreamPen ® (Dalim Biotech, Gangwon, South Korea), with a velocity of 5 km/h at a flow rate of 30 ml/min under a pressure of 7 bars, and capnoperitoneum of 12 mmHg was maintained for 30 min. As a result, RIPAC showed a wider distribution and stronger intensity than PIPAC. Compared with PIPAC, RIPAC demonstrated high values of the tissue concentration in the central, right upper, epigastrium, left upper, left lower, right lower, and right flank regions (median, 375.5-2124.9 vs. 161.7-1240 ng/ml; p  ≤ .05), and higher values of the depth of concentrated diffusion and depth of maximal diffusion (median, 232.5-392.7 vs. 116.9-240.1 μm; 291.2-551.2 vs. 250.5-362.4 μm; p  ≤ .05) in all regions except for bowels. In RIPAC, the pharmacokinetic properties reflected hemodynamic changes during capnoperitoneum, and there were no related toxicities. Conclusively, RIPAC may have the potential to enhance drug delivery into the peritoneum compared to PIPAC.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies